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Gait mechanics in patients with chronic
obstructive pulmonary disease
Jennifer M Yentes1*, Kendra K Schmid2, Daniel Blanke1, Debra J Romberger3,4, Stephen I Rennard4 and
Nicholas Stergiou1,2

Abstract
Background: Chronic obstructive pulmonary disease (COPD) is characterized by the frequent association of disease
outside the lung. The objective of this study was to determine the presence of biomechanical gait abnormalities in
COPD patients compared to healthy controls while well rested and without rest.
Methods: Patients with COPD (N = 17) and aged-matched, healthy controls (N = 21) walked at their self-selected
pace down a 10-meter walkway while biomechanical gait variables were collected. A one-minute rest was given
between each of the five collected trials to prevent tiredness (REST condition). Patients with COPD then walked at a
self-selected pace on a treadmill until the onset of self-reported breathlessness or leg tiredness. Subjects immediately
underwent gait analysis with no rest between each of the five collected trials (NO REST condition). Statistical models
with and without covariates age, gender, and smoking history were used.
Results: After adjusting for covariates, COPD patients demonstrated more ankle power absorption in mid-stance
(P = 0.006) than controls during both conditions. Both groups during NO REST demonstrated increased gait speed
(P = 0.04), stride length (P = 0.03), and peak hip flexion (P = 0.04) with decreased plantarflexion moment (P = 0.04) and
increased knee power absorption (P = 0.04) as compared to REST. A significant interaction revealed that peak ankle
dorsiflexion moment was maintained from REST to NO REST for COPD but increased for controls (P < 0.01). Stratifying
by disease severity did not alter these findings, except that step width decreased in NO REST as compared to REST
(P = 0.01). Standardized effect sizes of significant effects varied from 0.5 to 0.98.
Conclusions: Patients with COPD appear to demonstrate biomechanical gait changes at the ankle as compared to
healthy controls. This was seen not only in increased peak ankle power absorption during no rest but was also
demonstrated by a lack of increase in peak ankle dorsiflexion moment from the REST to the NO REST condition as
compared to the healthy controls. Furthermore, a wider step width has been associated with fall risk and this could
account for the increased incidence of falls in patients with COPD.
Keywords: Pulmonary disease, Locomotion, Joint kinematics, Joint kinetics, Biomechanics

Background
Chronic obstructive pulmonary disease (COPD) is a
worldwide health concern and is one of the few causes
of death that is on the rise [1]. COPD affects more than
the lungs and Fabbri and Rabe have emphasized the
‘systemic and complex abnormalities’ affecting peripheral
systems in patients with COPD [2]. One extra-pulmonary
manifestation of COPD is abnormal skeletal muscle
* Correspondence: jyentes@unomaha.edu
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structure (i.e., muscular dysfunction). Patients with
COPD suffer from abnormal body mass alterations,
muscle wasting/atrophy, impaired energy production
and metabolic performance, and increased susceptibility
to muscle fatigue and weakness [3-11].
Possibly related to abnormal skeletal muscle structure
is the decline in ambulatory activity that is common in
patients with COPD. Using the 6-minute walk distance
test, patients with COPD walked a significantly shorter
distance than aged-matched controls [12] and hospitalized
patients with COPD walked less than 10 minutes/day
during hospitalization and only up to 15 minutes/day
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after one month of discharge [13]. One third of patients
with severe COPD walked less than 15 minutes/day [14]
and when compared over a 12-hour time frame, walked
50% less than age-matched controls [15]. Ambulatory
activity may be limited in patients with COPD due to
neural and/or leg fatigue [16-18], suggesting muscular
dysfunction as a major contributor to limitation of
ambulation [19].
Gait abnormalities may be present in COPD that are
distinct from muscular weakness. Specifically, abnormalities in the biomechanics of the gait cycle may contribute
to altered ambulation. Our previous examination into
existing data consisting of subjective reports of gait abnormalities in patients with COPD, demonstrated that
the presence of COPD is associated with the report of a
limp, shuffle or other walking abnormality, which appeared to be related to COPD severity [20]. However,
objective analysis of gait mechanics in patients with
COPD has yet to be completed. Annegarn and colleagues used an accelerometer to assess gait during a 6minute walk test and demonstrated that cadence, walk
intensity and variability were related to the distance
walked in COPD patients [21]. More detailed analysis of
lower extremity joint muscular responses can be provided using advanced biomechanical analysis in the form
of joint angles, moments, and powers [22-24]. Joint moments can determine the net response of all muscle
groups in the lower extremities revealing crucial COPDrelated adaptations. Whereas, joint powers determine
the net contribution of all muscle groups at that joint.
This analysis has been used extensively to understand
the control mechanisms in healthy individuals and in
gait abnormalities of patients with cerebral palsy [25-27],
stroke [28-30], head injury [31-33] and other neuromuscular disorders [34-36].
Hence, the overall objectives of this study were to objectively and comprehensively characterize gait abnormalities present in patients with COPD. Utilizing the
mechanical analysis of joint angles, moments, and powers,
in addition to spatiotemporal gait parameters, in persons
with COPD and aged-matched controls, the presence of
abnormal gait patterns was assessed. Based upon our previous work [20], it was hypothesized that patients with
COPD would demonstrate decrements in their gait as
compared to healthy controls. Gait analysis was performed
in two conditions, REST and NO REST. The NO REST
condition was provided to the subjects to investigate an
activity-induced condition. Specifically, it was hypothesized that a lack of rest would exacerbate alterations in
gait mechanics. Furthermore, our previous study indicated
that disease severity, age, gender, and smoking history may
be associated with gait abnormalities in patients with
COPD. Thus, statistical models were used to limit the
effects of these potential confounding variables.
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Methods and materials
Patients with COPD were recruited from the Pulmonary
Clinical Studies Unit and general clinics of local hospitals. A FEV1/FVC ratio of 0.7 was used to define the
presence of COPD [37]. Participants were excluded if
there was a history of back or lower extremity injury or
surgery that affected the subject’s mobility or any other
process limiting the ability to walk, including neurological disease or impairment. In total, 17 patients with
COPD and 21 age-, height- and weight-matched healthy
controls were consented and participated in this study
(Table 1). The University Institutional Review Board and
the Institutional Review Board at the Omaha Veterans’
Affairs Medical Center approved all procedures and
written informed consent was obtained from all patients.

Protocol

To assess gait, reflective markers were placed on defined
anatomical locations, bilaterally, according to a modified
Helen Hayes marker set [38]. Participants were asked to
walk through a 10-meter walkway at a normal pace. To ensure that a complete footfall would be collected during each
trial, starting positions for each limb were determined prior
to data collection. Five trials were collected for each limb,
10 trials total. The 3D marker trajectories were collected
with a high-speed motion capture system (Motion Analysis
Corp., Santa Rosa, CA; 60 Hz). Ground reaction force data
from heel contact to toe off were collected using a piezoelectric force plate (Kistler Instrument Corp., Winterthur,
Switzerland; 600 Hz). All participants were given a minimum one-minute rest between each trial during the data
collection (REST condition).
All patients with COPD were then asked to determine
their self-selected pace on a treadmill at 0% incline. They
then walked at their chosen self-selected pace at 10% incline until the onset of self-reported breathlessness or
muscle tiredness (reported as either the development of
shortness of breath or the onset of subjective muscular
fatigue). Subjects were asked to walk until they felt like
they could not continue any further due to breathlessness
or muscle tiredness. This was a completely subjective interpretation. Motion capture data was not collected while
the subject walked on the treadmill. Once self-reported
breathlessness or muscle tiredness was reported, they were
immediately removed from the treadmill and asked to
walk through the 10-meter walkway, 5 times for each limb,
with no rest in between trials (NO REST condition). A
subset (n = 5) of healthy controls also went through the
NO REST condition in order to investigate the main effect
of condition in non-COPD group. Since these subjects
were not expected to indicate tiredness or breathlessness,
they were asked to walk for 15 minutes at a self-selected
speed on the treadmill at a 10% grade.
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Table 1 Subject characteristics
P

Control mean (SD) n = 21

COPD mean (SD) n = 17

Gender (n)

Male = 10

Male = 11

Age (years)

65.33 (7.67)

63.77 (8.55)

0.56

Height (cm)

165.89 (16.43)

171.97 (11.79)

0.21

Weight (kg)

78.85 (18.08)

90.58 (25.62)

0.11

FEV1/FVC

0.74 (0.04)

0.51 (0.16)

<0.001*

FEV1% Predicted

101.71 (11.00)

50.18 (21.0)

<0.001*

Current Smoker

2

5

Ex-Smoker

7

11

Smoking History (n)

Never Smoker

12

1

Control Rest Mean (SD)

Control No Rest Mean (SD)

COPD Rest Mean (SD)

COPD No Rest Mean (SD)

Speed (m/s)

1.09 (0.16)

1.07 (0.25)

1.11 (0.17)

1.15 (0.18)

Step Length (m)

0.66 (0.07)

0.65 (0.09)

0.66 (0.06)

0.66 (0.06)

Step Width (m)

0.11 (0.03)

0.11 (0.03)

0.12 (0.04)

0.11 (0.04)

Step Time (sec)

0.60 (0.06)

0.62 (0.06)

0.59 (0.06)

0.58 (0.06)

Stance Time (sec)

0.70 (0.09)

0.73 (0.08)

0.70 (0.10)

0.69 (0.09)

Support Time (sec)

0.11 (0.03)

0.12 (0.02)

0.12 (0.04)

0.11 (0.03)

Stride Length (m)

1.32 (0.14)

1.33 (0.17)

1.31 (0.13)

1.33 (0.13)

Stride Time (seconds)

1.19 (0.13)

1.22 (0.12)

1.18 (0.13)

1.15 (0.11)

Note: * indicates significance P < 0.05.

Data analysis

Gait variables were calculated from the five trials during
the stance phase of walking for each subject (Table 2).
Each marker’s three directions were filtered using the
Jackson algorithm [39] with cutoff values ranging from
2-8Hz. Visual 3D (C-Motion, Inc., Germantown, Maryland) was used for calculation of joint angles, moments,
and powers. A standing calibration was used to align the
local reference frames of the segments to the global reference frame. A hybrid model was built using anthropometric data from Dempster [40]. Custom programs
(MatLab 2007, Mathworks, Inc., Concord, MA) were
used to pick peak angles, moments, and powers from
calculated joint curves. In the REST condition, two
healthy controls and one patient with COPD did not
have a sufficient number of strides collected for spatiotemporal data analysis. One healthy control and one patient with COPD did not have a sufficient number of
strides collected for spatiotemporal data analysis in the
NO REST condition. They were removed for spatiotemporal analysis even though they were included in the
kinematic and kinetic analysis. One patient with COPD
could not complete the NO REST condition due to
exhaustion.
All variables were checked for normality and group
means of each dependent variable (Table 2) were calculated

for each group (control and COPD) and for each condition
(REST and NO REST). Four linear models were utilized on
each dependent variable in Table 2:
1) A 2x2 linear model with repeated measures for
condition was used to compare outcomes between
group (all COPD vs control) and condition (REST vs
NO REST) and to assess the group by condition
interaction.
2) The covariates of age, gender and smoking history
were added to model #1.
3) A 3x2 linear model with repeated measures for
condition was used to compare outcomes between
group (mild/moderate COPD vs severe/very severe
COPD vs control) and condition (REST vs NO
REST) and to assess the group by condition
interaction. Disease severity was defined using
GOLD standards [37]. Tukey’s method was used to
adjust for multiple comparisons.
4) The covariates of age, gender and smoking history
were added to model #3.
All statistical analysis was done using SAS version 9.3
(SAS Institute Inc., Cary, NC, USA). To control for the
unbalanced group sizes, the LS Means were calculated
and compared using SAS PROC MIXED. The significance
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Table 2 Dependent variables and their descriptions
Dependent variable

Description

Speed (m/s)

Measured as the derivative of the position of the sacral marker.

Step Length (m)

Anterior-posterior distance from the heel strike of the right foot to the heel strike of the left foot.

Step Width (m)

Medial-lateral distance from the heel strike of the right foot to the heel strike of the left foot.

Step Time (seconds)

Time from the heel strike of the right foot to the heel strike of the left foot.

Stance Time (seconds)

Time between heel strike and toe off for the right foot.

Double Support Time (seconds)

Timing of the heel strike of the left foot to the toe off of the right foot (terminal double support).

Stride Length (m)

Anterior-posterior distance from two consecutive right heel strikes.

Stride Time (seconds)

Time between two consecutive right heel strikes.

Peak Plantarflexion Angle (deg)

Minimum angle during early stance.

Peak Dorsiflexion Angle (deg)

Maximum positive angle during late stance.

Peak Knee Flexion Angle (deg)

Maximum positive angle during early to mid stance.

Peak Knee Extension Angle (deg)

Minimum angle (close to zero) during mid to late stance.

Peak Hip Flexion Angle (deg)

Maximum positive angle at very early stance.

Peak Hip Extension Angle (deg)

Minimum angle (close to zero) during late stance.

Peak Dorsiflexion Moment (N*m/kg)

Minimum rotational force during early stance.

Peak Plantarflexion Moment (N*m/kg)

Maximum rotational force during late stance.

Peak Knee Extension Moment (N*m/kg)

Maximum rotational force during mid stance.

Peak Knee Flexion Moment (N*m/kg)

Minimum rotational force during mid to late stance.

Peak Hip Extension Moment (N*m/kg)

Maximum rotational force during very early stance.

Peak Hip Flexion Moment (N*m/kg)

Minimum rotational force during late stance.

Peak Ankle Power Absorption 1 (W/kg)

Minimum energy absorbed during early stance.

Peak Ankle Power Absorption 2 (W/kg)

Minimum energy absorbed during mid to late stance.

Peak Ankle Power Generation (W/kg)

Maximum energy generated during late stance.

Peak Knee Power Absorption 1 (W/kg)

Minimum energy absorbed during early to mid stance.

Peak Knee Power Generation (W/kg)

Maximum energy generated during mid stance.

Peak Knee Power Absorption 2 (W/kg)

Minimum energy absorbed during late stance.

Peak Hip Power Generation 1 (W/kg)

Maximum energy generated during early stance.

Peak Hip Power Absorption (W/kg)

Minimum energy absorbed during mid to late stance.

Peak Hip Power Generation 2 (W/kg)

Maximum energy generated during late stance.

level was set at P < 0.05. Standardized effect sizes (ES)
were estimated as difference in LSMeans divided by the
standard deviation of the difference for all significant
findings.

Results
For model #1, a main effect of group was found for peak
hip power absorption at mid-stance (F1, 36 = 4.71, P =
0.04, ES = 0.7) in which patients with COPD absorb less
power than do controls. Several significant main effects
of condition were also found. In the REST condition,
peak knee power absorption during early stance (F1, 19 =
4.70, P = 0.04, ES = 0.5; Figure 1) was increased and peak
hip flexion angle (F1, 19 = 4.71, P =0.04, ES = 0.5; Figure 2),
peak knee flexion moment (F1, 19 = 5.07, P = 0.04, ES = 0.5;
Figure 3) and peak plantarflexion moment (F1, 19 = 5.12,

P = 0.04, ES = 0.5; Figure 3) were significantly decreased
as compared to the NO REST condition. In addition,
gait speed and stride length both significantly increased
in the NO REST condition as compared to the REST
condition (F1, 17 = 4.76, P = 0.04, ES = 0.5 & F1, 17 = 5.86,
P = 0.03, ES = 0.6 respectively). Lastly, a significant
interaction was found for peak ankle dorsiflexion moment in early stance (F1, 19 = 16.57, P = 0.007; Figure 4A).
Patients with COPD slightly decreased their dorsiflexion moment from REST to NO REST (Mean ± standard
error: −0.32 ± 0.32 to −0.31 ± 0.02 Nm/kg), whereas
healthy controls increased their dorsiflexion moment
from REST to NO REST (−0.35 ± 0.02 to −0.40 ±
0.02 Nm/kg).
When covariates were added (model #2), the hip no
longer demonstrated a group effect and instead a main

Yentes et al. Respiratory Research (2015) 16:31

Page 5 of 13

Energy
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B

Energy
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*

Figure 1 Sagittal plane joint power mean ensemble curves for the stance phase of gait for the: A) ankle, B) knee, and C) hip. Positive
values represent energy generation. Peak joint powers are shown in the bar graphs for the healthy controls rest (solid gray), healthy controls no
rest (striped gray), COPD rest (solid black), and COPD no rest (striped black). Note: * indicates significance (P < 0.05) at the indicated peak hip
power absorption at mid stance between the healthy controls and patients with COPD. This finding was significant when covariates were not
added to the model. Patients with COPD demonstrated less hip power absorption as compared to controls. § indicates significance (P < 0.05) at
the indicated peak ankle power absorption at mid stance between healthy controls and patients with COPD when covariates were added to
the model.

effect for group was found at the ankle. Peak ankle
power absorption during mid-stance was significantly
increased (F1, 32 = 8.80, P = 0.006, ES = 0.98) in patients
with COPD as compared to controls. Significant main
effects of condition found similar to those found in

model #1, with the exception of the peak knee power
absorption in early stance. Peak plantarflexion moment
(F1, 19 = 5.99, P = 0.02, ES = 0.53) was decreased and
peak hip flexion angle (F1, 19 = 4.98, P =0.04, ES = 0.5)
and peak knee flexion moment (F1, 19 = 5.22, P = 0.03,
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Figure 2 Sagittal plane joint angle mean ensemble curves for the stance phase of gait for the: A) ankle, B) knee, and C) hip. Positive
values represent dorsiflexion and flexion. Peak joint angles are shown in the bar graphs for the healthy controls rest (solid gray), healthy controls
no rest (striped gray), COPD rest (solid black), and COPD no rest (striped black). Note: ^ indicates a significant (P < 0.05) main effect of condition
(rest vs no rest) in the model without covariates whereas, # indicates the same main effect but in the model in which the covariates age, gender
and smoking history have been added. In both models, peak hip flexion angle is increased in the no rest condition.
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Figure 3 Sagittal plane joint moment mean ensemble curves for the stance phase of gait for the: A) ankle, B) knee, and C) hip. Positive
values represent plantarflexion and extension. Peak joint moments are shown in the bar graphs for the healthy controls rest (solid gray), healthy
controls no rest (striped gray), COPD rest (solid black), and COPD no rest (striped black). Note: ^ indicates a significant (P < 0.05) main effect of
condition (rest vs no rest) in the model without covariates whereas, # indicates the same main effect but in the model in which the covariates
age, gender and smoking history have been added. In both models, peak knee flexion moment is increased and peak ankle plantarflexion
moment is decreased in the no rest condition. ¥ indicates a significant (P < 0.05) interaction.
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Figure 4 Significant interaction for peak ankle dorsiflexion moment in early stance found in model #1 (A), model #2 (B), model #3 (C),
model #4 (D). In A and B, patients with COPD remain relatively stable and healthy controls change from REST to NO REST condition, increasing
(becoming more negative) their peak ankle dorsiflexion moment. In C and D, patients with COPD have been stratified for disease severity and
again, there is a similar pattern. Both mild/moderate and severe/very severe COPD patients maintain a similar peak ankle dorsiflexion moment
from REST to NO REST conditions whereas, the healthy controls increase (become more negative) in NO REST.

ES = 0.5) were significantly increased in NO REST as
compared to REST. Gait speed and stride length both
significantly increased in the NO REST condition as
compared to the REST condition (F1, 17 = 4.80, P = 0.04,
ES = 0.5 & F1, 17 = 5.80, P = 0.03, ES = 0.6, respectively).
The interaction for peak ankle dorsiflexion moment in
early stance maintained significance when covariates
were added to the model as well (F1, 19 = 17.10, P =
0.0006) (Figure 4B). Patients with COPD did not change
their dorsiflexion moment from REST to NO REST
(Mean ± standard error: −0.34 ± 0.03 Nm/kg for both)
but the healthy controls increased their dorsiflexion
moment across conditions (−0.33 ± 0.02 to −0.39 ±
0.03 Nm/kg).
In model #3, covariates were not used and patients
with COPD were stratified into disease severity classifications: mild/moderate and severe/very severe and compared to controls. No main effect for group was found.
Main effects for condition were found for similar variables as before. Peak plantarflexion moment (F1, 18 =
8.01, P = 0.01, ES = 0.6) was decreased and peak hip
flexion angle (F1, 18 = 5.59, P =0.03, ES = 0.5) and peak
knee power absorption during early stance (F1, 18 = 5.57,
P = 0.03, ES = 0.5) were significantly increased in NO
REST as compared to REST. Gait speed (F1, 16 = 6.72, P
= 0.02, ES = 0.6) and stride length (F1, 16 = 7.55, P = 0.01,
ES = 0.6) significantly increased in NO REST as compared
to REST. Step width (F1, 16 = 7.44, P = 0.01, ES = 0.6)

significantly decreased in NO REST as compared to REST.
A significant interaction for peak ankle dorsiflexion moment (F2, 18 = 8.19, P = 0.003) was found (Figure 4C). Patients with mild to moderate COPD did not change their
dorsiflexion moment (Mean ± standard error: −0.30 ±
0.03 Nm/kg for both) across conditions and patients with
severe to very severe COPD slightly decreased their moment (−0.34 ± 0.04 Nm/kg to −0.33 ± 0.04 Nm/kg) from
REST to NO REST. Healthy controls increased their
dorsiflexion moment significantly from −0.35 ± 0.02 Nm/
kg to −0.40 ± 0.03 Nm/kg from REST to NO REST.
The last model, #4, stratified patients with COPD into
disease severity and utilized the covariates of age, gender,
and smoking history. A main effect of group was found
for peak ankle power absorption during mid-stance. Patients with COPD had significantly increased (F2, 31 =
4.34, P = 0.02) power absorption at the ankle in midstance as compared to controls. Follow-up comparisons
reveal that severe/very severe COPD are increased as
compared to controls (t31 = 2.54, P = 0.04, ES = 0.8). No
significant differences were found between mild/moderate compared to controls or mild/moderate compared to
severe/very severe. Significant main effects of condition
found were identical to those found in model #3. Peak
plantarflexion moment (F1, 18 = 8.91, P = 0.008, ES =
0.65) was decreased and peak hip flexion angle (F1, 18 =
5.76, P =0.03, ES = 0.5) and peak knee power absorption
during early stance (F1, 18 = 5.50, P = 0.03, ES = 0.5) were

Yentes et al. Respiratory Research (2015) 16:31

significantly increased in NO REST as compared to
REST. The same spatiotemporal variables also demonstrated a main effect of condition. Gait speed (F1, 16 =
6.80, P = 0.02, ES = 0.6) and stride length (F1, 16 = 7.51, P
= 0.01, ES = 0.6) significantly increased in NO REST as
compared to REST. Step width (F1, 16 = 7.44, P = 0.01,
ES = 0.6) significantly decreased in NO REST as compared to REST. A significant interaction for peak ankle
dorsiflexion moment (F2, 18 = 8.43, P = 0.003) was found
(Figure 4D). Patients with mild to moderate COPD
(Mean ± standard error: −0.32 ± 0.04 Nm/kg for both
conditions) and severe to very severe COPD (−0.36 ±
0.04 Nm/kg for both conditions) did not change their
dorsiflexion moment across conditions. Healthy controls
increased their dorsiflexion moment significantly from
−0.34 ± 0.03 Nm/kg to −0.40 ± 0.03 Nm/kg from REST
to NO REST.

Discussion
The purpose of this experiment was to characterize biomechanical gait abnormalities in patients with COPD as
compared to their healthy counterparts. Contrary to our
hypothesis, patients with COPD demonstrated minimal
significant differences in biomechanical gait analysis
when walking under a REST condition (only one main
effect of group was found for all dependent variables in
models #1, #2, and #4). Patients with COPD do demonstrate biomechanical gait changes at the ankle as compared to healthy controls. This was seen not only in
peak ankle power absorption during NO REST but also
patients with COPD demonstrate a lack of increase in
peak ankle dorsiflexion moment from the REST to the
NO REST condition as compared to the healthy controls. We had hypothesized that they would indeed suffer from gait decrements based on our previous findings
[20]. During our previous study, we had investigated the
presence of gait abnormalities reported in the publicly
available NHANES III dataset and the gait abnormalities
reported were subjective and based on observation. The
lack of significant findings in the current study may be
related to the inherent heterogeneity in which COPD
presents itself clinically. Recently, several potential phenotypes (subset) of the COPD syndrome have been identified including a clinical phenotype (age, gender,
smoking history), physiological (rapid decline in FEV1),
radiographic or imaging (structural abnormalities), acute
exacerbation of COPD, systemic inflammation, and the
presence of co-morbidities (cardiovascular disease, metabolic syndrome, osteoporosis, diabetes, depression)
[41,42]. Thus, it cannot yet be concluded that there is
no difference between the gait of healthy controls and
patients with COPD in a REST condition, except at the
ankle, and such differences may be a feature of specific
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subset (s) of COPD patients. Further work is needed to
clearly define these differences.
The secondary aim was to examine the effect of NO
REST on the biomechanical gait parameters of patients
with COPD. Based on previous reports of increased
presence of muscular fatigue in patients with COPD
[4,43], we had hypothesized that their gait would significantly decrement under a NO REST condition as inducing activity may lead to fatigue. Several parameters
statistically changed from the REST to NO REST condition for both groups. In the NO REST condition, speed
and stride length increased potentially explaining the increased hip flexion angle and knee power absorption at
early stance during the NO REST condition. Thus, as
the subjects walked faster and took longer steps, their
hip would flex more and the knee would absorb more of
the energy generated from the increased walking speed.
It should be noted that even though both groups walked
faster under the NO REST condition, the mean increases
in gait speed and stride lengths were quite small, although statistically significant. In addition, the peak
ankle plantarflexion moment at push-off decreased for
both groups during the NO REST condition.
Interestingly, a significant interaction was found for
peak ankle dorsiflexion moment at early stance no matter
the statistical model employed. Patients with COPD maintained the same amount of torque in their dorsiflexors
from REST to NO REST whereas the healthy controls increased (more negative) their peak dorsiflexion torque in
the NO REST condition. For the healthy controls, this
makes sense as speed has increased in the NO REST condition, an increased dorsiflexion moment would be needed
to control the lowering of the forefoot to the ground.
Based on these findings, it appears that the patients with
COPD may have problems in controlling the foot shortly
after heel strike. Additionally, the longer stride lengths
noted in the NO REST condition may place the tibialis anterior under greater mechanical demand and this along
with possible muscular fatigue could account for the lack
of change in patients with COPD. Muscular fatigue during
various physical activities has been reported in patients
with COPD [4,44] and up to 40% of patients present with
muscular fatigue as their main barrier to physical activity
[16]. From the current study, we cannot determine if our
findings are truly due to muscular fatigue. The NO REST
condition was an activity-induced condition and was not a
true fatigue-induced condition and may have been more
of a mild exercise or warm-up type condition. Yet, muscular fatigue could have been present although this was not
investigated in this study. Future work could investigate
fatigue through more demanding protocols or through the
use of instrumented treadmills, in which steps from the
beginning of a trial are compared to steps at the end of a
trial when fatigue is reported.
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Overall, the models were very similar in findings. Only
slight differences were found with the introduction of
the covariates of age, gender, and smoking history. In
model #1, the hip was found to be significantly different
yet upon adding covariates (model #2), the hip was no
longer significant but the ankle was found to be significant. In model #1, the ankle was almost significant, P =
0.07. When the covariates were added, there was a significant age effect (P = 0.003), so after adjusting for age,
there was no difference between groups for the hip, that
difference was confounded with age. With the ankle, it
was marginally significant in model #1, and became even
more pronounced after adjusting for the effect of age,
model #2. A similar finding was found with models #3
and #4. A group effect for the ankle was found in model
#4 that was not seen in model #3. Without the covariates (model #3), the ankle was marginally significant P =
0.11, and after adjusting for the effect of age, it became
more pronounced and reached significance. Based upon
these findings, age was the only covariate that had an
impact on the overall findings. This is expected as aging
does have an effect on gait [45]. Gender and smoking
history did not confound any of the findings. Gender differences in biomechanical gait studies are typically not
reported; however, a few studies have noted differences
between genders [46,47]. It is interesting to note that
smoking did not affect the findings, as smoking is associated with increased systemic inflammation, which is
thought to be a possible mechanism of change in the
structure and function of skeletal muscle in patients with
COPD [48,49].
In COPD, decreased mitochondrial density and fractional area in the vastus lateralis with decreased oxidative enzymes leads to decreased oxidative capacity
[10,50]. Further, oxidative damage, possibly leading to atrophy and muscle wasting [51] has been documented,
along with muscle fiber type shifting, where oxidative
fiber type (type-I) shifted to glycolytic fiber types (typeII) [4,6,52]. In contrast, it has been shown that the more
distal tibialis anterior has normal fractional area and oxidative capacity despite decreased mitochondrial density
[50]. Yet, two recent articles demonstrate that muscle
weakness is present in the ankle dorsiflexors and plantarflexors, greater than weakness present in the quadriceps of patients with COPD [53,54] and that this
weakness is related to changes in muscle structure [54].
Multiple factors could be at play affecting muscle dysfunction and structural changes in COPD [55]. The two
most popular schools of thought are 1) disuse and 2)
chronic systemic inflammation. However, no conclusive
research has yet to be done and appears that possibly a
mix of the two mechanisms may be at play and/or two
phenotypes exist within the disease. In addition, it is
feasible that blood flow and possible changes in blood
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gasses that are not generally regarded as clinically important could also play a role [56]. Although, for patients
with COPD, peripheral muscle oxygenation is not compromised during submaximal exercise [57], rather exercise capacity is limited due to disuse and poor lung
function (breathlessness).
A curious and interesting finding during the NO REST
condition is that of the changes in step width. In models
#3 and #4 when disease severity was entered into the
statistical models, it was shown that step width decreased significantly in NO REST as compared to REST.
The step width of patients with COPD was narrower in
the NO REST condition as compared to their REST condition. Patients with mild to moderate COPD walked
with a wider step width under both conditions as compared to controls and patients with severe to very severe
COPD. Walking with a wider step could be done as an
attempt to increase the base of support during the
double support phase of gait. As reported in the introduction, fall risk is increased in patients with COPD
[58-61] and changes in step width have been found to be
associated with fall risk [62-65]. It appears though that
step width variability is the dependent variable associated with fall risk rather than just a mean change in step
width [66-68]. Future studies should examine step width
variability in patients with COPD and the association of
this variability with fall risk and fear of falling.
A limitation of the current study is the heterogeneity
of the manifestations of COPD [69-71]. While COPD is
defined in terms of fixed airflow limitation, COPD is also
characterized by the frequent but extremely variable association of disease outside the lungs [72,73]. Among
these, muscle fatigue is a common symptom associated
with mild to moderate COPD patients irrespective of
lung function, anthropometric data or quadriceps
strength [74]. Contributing factors to leg fatigue could
be related to abnormal structure and function of muscle
tissue in COPD [4,6,9,10]. A gauge of exhaustion or fatigue was not utilized in this study and should be
considered in future work. Moreover, several other
co-morbidities have been associated with COPD such as
osteoporosis [75-77], diabetes [78,79], as well as anxiety
and depression [12,80-82], which also associated with
gait abnormalities. This does not include the other phenotypes of the disease that have been proposed [41,42].
Likewise, it is possible that our healthy controls did indeed have an associated co-morbidity that would likely
result in altered gait mechanics as well. Although all
patients were screened by a nurse practitioner before
inclusion into the study, it is possible that not all
co-morbidities were included in our exclusion criteria.
Future studies should focus on the inclusion of just patients with severe disease or increase the sample size for
each disease severity.
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Conclusions
The novel finding of this study was that patients with COPD
do indeed demonstrate biomechanical gait alterations when
walking under a NO REST or activity-induced condition.
These documented changes were loss of function at the
ankle joint, in that peak ankle dorsiflexion moment did not
increase under the NO REST condition as it did in the control sample. Although fatigue was not directly measured in
the current study, it is feasible that the patients with COPD
did present with leg fatigue when activity was induced. Biomechanical gait analysis can provide insight into the joint
muscular responses and contributions to movement, providing insight into mechanisms of functional limitations in these
patients. Moreover, considering the heterogeneity of COPD,
it is possible that a subset of COPD patients, too small to
have meaningful inclusion in the current study, may manifest
differences not observed in the larger group. Future work
should focus on investigating the effects of muscular fatigue
and associations with biomechanical gait decrements in this
population. In addition, future work should examine biomechanical abnormalities in the different phenotypes associated with the diagnosis of COPD as some subsets of patients
may present with gait abnormalities and some patients may
not. Lastly, the finding of widened step width in patients with
COPD in the REST condition is of particular interest. The
increased incidence of falls in patients with COPD has been
reported and step width has been indicated as a factor in fall
risk. Further investigations into the association of step width
variability and fear of falling and fall risk in patients with
COPD could reveal significant findings as well as lead to
innovative rehabilitation techniques.
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